{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06150976",
            "orgStudyIdInfo": {
                "id": "HCC 23-043"
            },
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "MAAT For Young Adult Cancer Survivors",
            "officialTitle": "Modifying Memory and Attention Adaptation Training (MAAT) For Young Adult Childhood Cancer Survivors",
            "acronym": "MAAT-YACCS",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "maat-for-young-adult-cancer-survivors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-10",
            "studyFirstSubmitQcDate": "2023-11-27",
            "studyFirstPostDateStruct": {
                "date": "2023-11-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Robert J Ferguson, PhD",
                "investigatorTitle": "Assistant Professor of Medicine",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "University of Pittsburgh",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "St. Jude Children's Research Hospital",
                    "class": "OTHER"
                },
                {
                    "name": "Indiana University School of Medicine",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.",
            "detailedDescription": "The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits.\n\nThis pilot trial will determine MAAT-YS feasibility, treatment satisfaction and size of effect in self-report and objective measures of neurocognitive function.\n\nEligible participants will be 9 individuals who were diagnosed with non-central-nervous system (CNS) cancer (including leukemia/lymphoma without known CNS involvement) prior to the age of 18, are at least 1-year from completion of cancer treatment, including chemotherapy.\n\nParticipants will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.\n\nIf successful, further research is planned with a larger, multi-site randomized controlled trial of MAAT-YS."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer"
            ],
            "keywords": [
                "Cancer",
                "cancer survivorship",
                "cancer-related cognitive impairment",
                "CRCI",
                "Cognitive-behavioral therapy",
                "Memory Attention and Adaptation Training"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 9,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MAAT-YS Group",
                    "type": "EXPERIMENTAL",
                    "description": "This group will be treated with the MAAT-YS cognitive-behavioral therapy.",
                    "interventionNames": [
                        "Behavioral: MAAT-YS"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "MAAT-YS",
                    "description": "MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.",
                    "armGroupLabels": [
                        "MAAT-YS Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Perceived Cognitive Impairments Scale (PCI)",
                    "description": "The PCI assesses perceived cognitive function of participants within a timeframe of the previous 7 days. It consists of 18 items with a 5-point Likert-type rating of 0 (Never) to 4 (Several times a day) with a scoring range of 0-72. Scoring instructions indicate items are reverse scored, such that higher scores denote better perceived cognitive function, lower scores, poorer cognitive function.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (1) Verbal Memory (VBM) (recognition memory for words)",
                    "description": "CNSVS Verbal Memory (VBM) is a computer-based neuropsychological test of word recognition and memory for words). The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (2) Symbol Digit Coding (SDC) (visual motor processing speed)",
                    "description": "CNSVS Symbol Digit Coding (SDC) is a computer-based neuropsychological test of visual motor processing speed. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (3) Stroop Test (ST) (visual motor reaction time, processing speed and visual discrimination)",
                    "description": "CNSVS Stroop Test (ST) is a computer-based neuropsychological test of visual motor reaction time, processing speed and visual discrimination. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "CNS Vital Signs (CNSVS) Online Neuropsychological Test Battery (4) 4-Part Continuous Performance Test (FPCPT) (sustained attention and working memory)",
                    "description": "CNSVS 4-Part Continuous Performance Test (FPCPT) is a computer-based neuropsychological test of sustained attention and working memory. The test is measured in standard score units (Mean of 100; SD 15). Higher scores denote better cognitive function.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT visits)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) v.3. Impact on Quality-of-Life Scale (IQOL)",
                    "description": "The IQOL assesses perceived quality of life impact of cognitive symptoms participants experience within a timeframe of the previous 7 days. It consists of 4 items with a 5-point Likert-type rating of 0 (Not at all) to 4 (Very Much) with a scoring range of 0-16. Scoring instructions indicate items are reverse scored, such that higher scores denote better quality of life, lower scores, poorer quality of life.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Cognitive-Symptom-Checklist-Work-21 (CSC-W-21)",
                    "description": "The CSC-W-21 is a 21-tem self-report measure of perceived impact of cognitive symptoms on work (occupational)-related tasks. Respondents are asked to indicate \"yes\" (1 point) or \"no\" (0 points) to each item. Higher scores, ranging from 0-21, denote more work-related cognitive symptoms.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Metamemory in Adulthood-Anxiety Scale (MIA-A)",
                    "description": "The MIA-A is a 14-item scale that uses a 5-point Likert-type rating for each item (1= Disagree Strongly; 5 Agree Strongly) with item 13 reverse scored. Items are summed with higher scores (range from 14-70) denoting more anxiety associated with perceived cognitive problems in daily life.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety v.1. - Short Form 4a",
                    "description": "The PROMIS Anxiety v.1 Short Form 4a scale evaluates self-reported fearfulness, cognitive focus, and concentration, as well as emotional distress related to worry and feeling uneasy over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10).Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more anxiety.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS) Depression v.1. - Short Form 4a",
                    "description": "The PROMIS Depression v.1 Short Form 4a scale evaluates self-reported negative mood, helpless and worthlessness over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more depression.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue v.1. - Short Form 4a",
                    "description": "The PROMIS Fatigue v.1 Short Form 4a scale evaluates self-reported symptoms of exhaustion, fatigue and interference with daily activity over the past 7 days. It consists of 4 items, each rated on a 5-point scale (1=not at all; 2=a little bit; 3=somewhat; 4=quite a bit; and 5=very much) with a scoring range of 4 to 20. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote more anxiety.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Physical 2a",
                    "description": "The PROMIS Global Health Physical scale is a self-report measure assessing physical health and ability. It consists of 2 items with a 5-point Likert-type rating of 1 (Poor) to 5 (Excellent) with a scoring range of 2-10. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote better physical health.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2. Global Health - Mental 2a",
                    "description": "The PROMIS Global Health Mental scale is a self-report measure assessing mental health and ability. It consists of 2 items with a 5-point Likert-type rating of 1 (Poor) to 5 (Excellent) with a scoring range of 2-10. Raw scores are converted to T-scores using PROMIS norms (mean = 50; SD = 10). Higher scores denote better mental health.",
                    "timeFrame": "Baseline to Post-Treatment (after 8 weekly telehealth MAAT-YS visits)"
                },
                {
                    "measure": "Credibility/Expectancy Questionnaire (CEQ)",
                    "description": "The CEQ is a self-report measure assessing the credibility and expectancy of treatment received. It consists of 6 items, 4 items with a 9-point Likert-type rating of 1 (not at all) to 5 (very much) with a scoring range of 3-27. The other 2 items are on a percentage scale from 0%-100% in increments of 10 with a scoring range of means 0-100%. Higher scores denote higher treatment credibility and expectancy.",
                    "timeFrame": "Only administered after Visit 6 of MAAT-YS (after 6 weeks)"
                },
                {
                    "measure": "Treatment Satisfaction Questionnaire (TSS)",
                    "description": "The Treatment Satisfaction (TSS) questionnaire is a self-report measure assessing satisfaction of treatment. It consists of 5 items with a 5-point Likert-type rating of 0 (not at all) to 8 (completely) with a scoring range of 0-40 and 1 additional yes/no item about whether traveling for treatment is possible for participation. Higher scores denote more satisfaction with treatment.",
                    "timeFrame": "Post-MAAT-YS treatment only (8 weeks)"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "MAAT-YS Fidelity Checklists",
                    "description": "The MAAT-YS Fidelity Checklists assess the degree to which the MAAT-YS study clinician adheres to specific therapeutic behaviors of the MAAT-YS Clinician Manual. The checklists are administered to 2 independent treatment adherence raters who review randomly selected audio recordings of each of the 8 telehealth-delivered MAAT-YS visits. Behaviors in checklists per each visit are independently rated 0 (no or poor fidelity) to 10 (highest fidelity possible). Rating means are computed for each visit for a score of 0-10 with higher scores denoting higher treatment fidelity.",
                    "timeFrame": "Immediately after the 6th visit of the MAAT intervention (6 weeks)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults aged 18-39\n2. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement\n3. At least 1 year after completion of treatment including chemotherapy, cancer-free\n4. English fluent\n5. Memory or other cognitive problems attributed to cancer and/or cancer treatment\n6. Score of \\<10 on the FACT-Cog Impact on Quality of Life Scale\n7. Willing to use telehealth with internet access\n8. Willing to provide informed consent to participation\n\nExclusion Criteria:\n\n1. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;\n2. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;\n3. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59\n4. Severe uncorrected sensory impairment (severe hearing or visual impairment).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "39 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chloe A Sinagra",
                    "role": "CONTACT",
                    "phone": "412-623-5888",
                    "email": "chloe.sinagra@pitt.edu"
                },
                {
                    "name": "Robert J Ferguson, PHD",
                    "role": "CONTACT",
                    "email": "fergusonrj2@upmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert J Ferguson, PHD",
                    "affiliation": "UPMC Hillman Cancer Center/University of Pittsburgh School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Indiana University School of Medicine",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brenna Brenna, PsyD",
                            "role": "CONTACT",
                            "phone": "317-963-7502",
                            "email": "mcdonalb@iupui.edu"
                        },
                        {
                            "name": "Jessica N. Bailey, BS",
                            "role": "CONTACT",
                            "phone": "317-963-7516",
                            "email": "jnadkins@iupui.edu"
                        },
                        {
                            "name": "Brenna C. McDonald, PsyD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "University of Pittsburgh School of Medicine/UPMC Hillman Cancer Center",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chloe A Sinagra",
                            "role": "CONTACT",
                            "phone": "412-623-5888",
                            "email": "chloe.sinagra@pitt.edu"
                        },
                        {
                            "name": "University OPSOMHC Center, PHD",
                            "role": "CONTACT",
                            "phone": "412-623-5888",
                            "email": "fergusonrj2@upmc.edu"
                        },
                        {
                            "name": "Robert J. Ferguson, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105-3678",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tara Brinkman, PHD",
                            "role": "CONTACT",
                            "phone": "901-595-5891",
                            "email": "tara.brinkman@stjude.org"
                        },
                        {
                            "name": "Stephanie Guthrie, RN, BSN, CCRP",
                            "role": "CONTACT",
                            "phone": "901-595-5143",
                            "email": "stephanie.guthrie@stjude.org"
                        },
                        {
                            "name": "Tara Brinkman, PHD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "There is no data sharing plan with other institutions for this pilot trial."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M29705",
                    "name": "Cognitive Dysfunction",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}